naion and semaglutide use linked with increased risk for in patients with diabetes Semaglutide Tied to Increased NAION

doi:10.3390/diseases12090204 24

Slow and steady discontinuation Stopping GLP-1 medications abruptly may lead to rapid weight regain

Discontinuing treatment often leads to weight regain, so ongoing therapy with periodic dose adjustments maintains your results

Theyll be able to monitor your progress and provide clinical guidance on unwanted reactions and side effects

This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase Review (18 RCTs, n=27,949) found semaglutide results in a clinically relevant weight loss at mediumterm followup vs placebo, likely to be sustained in long term while on treatment